There are currently 428 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
MIRAI-MRI: Comparing Screening MRI for Patients at High Risk for Breast Cancer Identified by Mirai and Tyrer-Cuzick
NCT05968157
Recruiting
Accurate risk assessment is essential for the success of population screening programs and early detection efforts in breast cancer. Mirai is a new deep learning model based on full resolution mammograms. Mirai is a mammography-based deep learning model designed to predict risk at multiple timepoints, leverage potentially missing risk factor information, and produce predictions that are consistent across mammography machines. Mirai was trained on a large dataset from Massachusetts General Hospi... Read More
Gender:
FEMALE
Ages:
40 years and above
Trial Updated:
12/04/2024
Locations: UMass Medical School, Worcester, Massachusetts
Conditions: Breast Cancer
Register for Updates
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
NCT06322888
Recruiting
The goal of this study is to learn more about how exercise might lower the risk of developing breast cancer in women with dense breast tissue by studying changes that occur in breast tissue and blood as a result of participating in an exercise program. The names of the study groups in this study are: * Exercise Training Group * Waitlist Control Group
Gender:
FEMALE
Ages:
Between 18 years and 59 years
Trial Updated:
12/04/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Breast Cancer, Breast Cancer Female
Register for Updates
Tumor-Derived FGF19
NCT06068257
Recruiting
Identify and test thresholds, specificity and sensitivity for a potential cancer associated biomarker protein, FGF19, (and associated markers) for detection in human blood in the blood of breast and colorectal in cancer patients, and see if occurs at higher rates than healthy controls
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: Burnett School Biomedical Sciences, Orlando, Florida
Conditions: Colorectal Cancer, Breast Cancer, Healthy
Register for Updates
Breast Cancer AI Imaging Study
NCT06604078
Recruiting
This study aims to develop a social health platform called MammoChat (https://MammoChat.com) that allows patients to share their real-world patient data to a trusted network for development of clinical intelligence to improve patient outcomes. Therefore: 1. The investigator will establish a Discourse social network where patients can anonymously and securely share their breast imaging and interact with other patients. 2. The investigator will use standardized questionnaires to understand the im... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: University of Central Florida, Orlando, Florida
Conditions: Breast Cancer, Breast Cancer Screening
Register for Updates
Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).
NCT05957042
Recruiting
To find out if contrast enhanced ultrasound (CEUS) can be used to determine if patients receiving combined ICI therapy for triple negative breast cancer (TNBC) are responding to treatment earlier than standard of care MR or CT.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/02/2024
Locations: Penn State Health College of Medicine, Hershey, Pennsylvania
Conditions: Breast Cancer, Contrast Enhanced Ultrasound
Register for Updates
Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer
NCT05736367
Recruiting
To analyze the metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2024
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey +1 locations
Conditions: Breast Cancer
Register for Updates
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
NCT06517212
Recruiting
This trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-), node-positive (N+) high risk early breast cancer patients with obesity or overweight, inhibiting the growth and survival of micrometastatic disease and leading to clearance of tumor-informed circulating tumor DNA (ctDNA) and freedom from the development of metastatic disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2024
Locations: Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas
Conditions: Breast Cancer, Breast Neoplasms, Breast Cancers
Register for Updates
GammaPod Dose Escalation Radiation for Early Stage Breast Cancer
NCT04234386
Recruiting
The GammaPod machine was made by Xcision Medical Systems and is already FDA cleared to deliver focused radiation within the breast. Unlike current radiation machines, the GammaPod was designed specifically for treating breast cancer. The GammaPod can pinpoint radiation to the tumor bed in the breast which lowers the amount of radiation to nearby tissues. The machine uses a breast cup system to hold the breast in place for the treatment. This breast cup system was tested at MSGCCC (Marlene Stewar... Read More
Gender:
FEMALE
Ages:
45 years and above
Trial Updated:
11/25/2024
Locations: UMMC, Baltimore, Maryland +3 locations
Conditions: Breast Cancer
Register for Updates
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC
NCT06263543
Recruiting
The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal growth factor 2 low (HER2 low) breast cancer. Although SG is approved to treat metastatic HR+/HER2 negative breast cancer, the aim of this study is to determine if SG is still effective specifically in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/21/2024
Locations: UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California +2 locations
Conditions: Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer
Register for Updates
Video Education With Result Dependent dIsclosure
NCT05225428
Recruiting
The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more diverse patient population at risk for hereditary cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/20/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Genetic Testing, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Colorectal Cancer, Renal Cancer, Melanoma, Sarcoma
Register for Updates
Postoperative Opt-In Narcotics Treatment in Breast
NCT05078398
Recruiting
In a recent study, researchers let patients choose what medications to go home with after endocrine surgery. This has not been done in outpatient breast surgery, though several institutions have moved towards avoiding opioids altogether after breast surgery. These institutions only prescribed rescue opioids upon request. The aim of this study is to compare a similar "opt-in" protocol for narcotics to usual care (where patients are routinely discharged with opioids) for outpatient breast surgery... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: UCLA Ronald Reagan Medical Center, Los Angeles, California +1 locations
Conditions: Breast Cancer, Breast Surgery, Opioid Use
Register for Updates
Comparison of CE-DBT and MRI in Patients With Known Breast Lesions
NCT05754749
Recruiting
The purpose of this pilot study is to compare radiologist confidence level in evaluating patients with known breast lesions between contrast enhanced digital breast tomosynthesis (CE- DBT) and contrast enhanced dynamic magnetic resonance imaging (CE-MRI) acquired as a part of a standard clinical workup.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/19/2024
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Breast Cancer
Register for Updates